• Something wrong with this record ?

New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia

J. Bertrand, H. Dostálová, V. Krystof, R. Jorda, A. Castro, J. Mella, C. Espinosa-Bustos, A. María Zarate, CO. Salas

. 2020 ; 94 (-) : 103361. [pub] 20191017

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV17-31834A MZ0 CEP Register

Bcr-Abl and Btk kinases are among the targets that have been considered for the treatment of leukemia. Therefore, several strategies have focused on the use of inhibitors as chemotherapeutic tools to treat these types of leukemia, such as imatinib (for Bcr-Abl) or ibrutinib (for Btk). However, the efficacy of these drugs has been reduced due to resistance mechanisms, which have motivated the development of new and more effective compounds. In this study, we designed, synthesized and evaluated 2,6,9-trisubstituted purine derivatives as novel Bcr-Abl and Btk inhibitors. We identified 5c and 5d as potent inhibitors of both kinases (IC50 values of 40 nM and 0.58/0.66 μM for Abl and Btk, respectively). From docking and QSAR analyses, we concluded that fluorination of the arylpiperazine system is detrimental to the activity against two kinases, and we also validated our hypothesis that the substitution on the 6-phenylamino ring is important for the inhibition of both kinases. In addition, our studies indicated that most compounds could suppress the proliferation of leukemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos cells) at low micromolar concentrations in vitro. Finally, we preliminarily demonstrated that 5c inhibited the downstream signaling of both kinases in the respective cell models. Therefore, 5c or 5d possessed potency to be further optimized as anti-leukemia drugs by simultaneously inhibiting the Bcr-Abl and Btk kinases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012937
003      
CZ-PrNML
005      
20210507101652.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bioorg.2019.103361 $2 doi
035    __
$a (PubMed)31699386
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bertrand, Jeanluc $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
245    10
$a New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia / $c J. Bertrand, H. Dostálová, V. Krystof, R. Jorda, A. Castro, J. Mella, C. Espinosa-Bustos, A. María Zarate, CO. Salas
520    9_
$a Bcr-Abl and Btk kinases are among the targets that have been considered for the treatment of leukemia. Therefore, several strategies have focused on the use of inhibitors as chemotherapeutic tools to treat these types of leukemia, such as imatinib (for Bcr-Abl) or ibrutinib (for Btk). However, the efficacy of these drugs has been reduced due to resistance mechanisms, which have motivated the development of new and more effective compounds. In this study, we designed, synthesized and evaluated 2,6,9-trisubstituted purine derivatives as novel Bcr-Abl and Btk inhibitors. We identified 5c and 5d as potent inhibitors of both kinases (IC50 values of 40 nM and 0.58/0.66 μM for Abl and Btk, respectively). From docking and QSAR analyses, we concluded that fluorination of the arylpiperazine system is detrimental to the activity against two kinases, and we also validated our hypothesis that the substitution on the 6-phenylamino ring is important for the inhibition of both kinases. In addition, our studies indicated that most compounds could suppress the proliferation of leukemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos cells) at low micromolar concentrations in vitro. Finally, we preliminarily demonstrated that 5c inhibited the downstream signaling of both kinases in the respective cell models. Therefore, 5c or 5d possessed potency to be further optimized as anti-leukemia drugs by simultaneously inhibiting the Bcr-Abl and Btk kinases.
650    _2
$a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a bcr-abl fúzní proteiny $x antagonisté a inhibitory $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a leukemie $x patologie $x prevence a kontrola $7 D007938
650    _2
$a puriny $x chemie $x farmakologie $7 D011687
650    _2
$a kvantitativní vztahy mezi strukturou a aktivitou $7 D021281
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dostálová, Hana $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic
700    1_
$a Krystof, Vladimir $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic. Electronic address: vladimir.krystof@upol.cz
700    1_
$a Jorda, Radek $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic
700    1_
$a Castro, Alejandro $u Laboratorio de Bioproductos Farmacéuticos y Cosméticos, Centro de Excelencia en Medicina Traslacional, Facultad de Medicina, Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco 4780000, Chile
700    1_
$a Mella, Jaime $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, 2360102, Av. Gran Bretaña 1111, Playa Ancha, Valparaíso, Casilla 5030, Chile
700    1_
$a Espinosa-Bustos, Christian $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
700    1_
$a María Zarate, Ana $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
700    1_
$a Salas, Cristian O $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile. Electronic address: cosalas@uc.cl
773    0_
$w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 94, č. - (2020), s. 103361
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31699386 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101652 $b ABA008
999    __
$a ok $b bmc $g 1651169 $s 1133316
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 94 $c - $d 103361 $e 20191017 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
GRA    __
$a NV17-31834A $p MZ0
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...